Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
NCT03786094 · Spexis AG · PHASE3 · terminated · last registry update 2023-11-01 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was halted early due to failure to meet the primary endpoint.” | – | Registry record, Spexis AG |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TUBB4B in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-04-24Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-B01D1 + Eribulin (NCT06382142)
- 2024-04-18Results posted on the registry: Adrienne G. Waks, Vinorelbine + Trastuzumab (NCT03414658)
- 2024-04-03Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-B01D1 + Eribulin (NCT06343948)
- 2024-02-28Phase 3 first posted: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., SKB264 + Paclitaxel (NCT06279364)
- 2023-10-10Phase 3 first posted: BriaCell Therapeutics Corporation, SV-BR-1-GM + Cyclophosphamide (NCT06072612)
- 2023-06-15Results posted on the registry: Daiichi Sankyo, Trastuzumab deruxtecan (DS-8201a) + Capecitabine (NCT03734029)
- 2023-04-14Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., SHR-A1811 + Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel (NCT05814354)
- 2022-12-28Results posted on the registry: Dana-Farber Cancer Institute, Eribulin + Adriamycin (NCT02623972)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision